OnKure Therapeutics, Inc.
About OnKure Therapeutics, Inc.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2024
- $0
- Net income
- -$59.5M
- Total assets
- $62.1M
- Market cap
- $169.3M
- Operating margin
- -1833.7%
- Net margin
- -1733.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $3.4M
- Operating expenses
- $63.0M
- Operating income
- -$63.0M
- Income tax
- $0
- Net income
- -$59.5M
- EPS (basic)
- $-4.40
- EPS (diluted)
- $-4.40
Balance sheet
- Total assets
- $62.1M
- Current assets
- $60.8M
- Total liabilities
- $5.9M
- Current liabilities
- $5.9M
- Shareholders’ equity
- $56.2M
Cash flow
- Operating cash flow
- -$51.8M
- Investing cash flow
- -$46.0K
- Financing cash flow
- $163.0K
- Net cash flow
- -$51.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $169.3M
- EPS (diluted)
- $-4.4
- Shares outstanding
- 38.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Oct 7, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $59.5M in FY2024.
- Trading 17% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review OnKure Therapeutics, Inc..
Write a review
News about OnKure Therapeutics, Inc.
News & sentiment via Polygon.io
